Respiratory failure due to acute respiratory distress syndrome (ARDS) is one of the major causes of mortality (53%) associated with COVID-19 disease (1) . Around 10 % of the patients require intensive care unit (ICU) care with ventilatory support and an ICU mortality rate of 79% has been reported (2, 3) .
The severity of the disease is higher in older patients with 80 % death observed in those over 60-65 years of age (1, 4) , while younger infected seem to be less susceptible and exhibit medium-mild symptoms (23). Once the lower respiratory tract is affected, the respiratory distress progresses very quickly, with time to death reported as rapidly as 14 days from initial symptoms despite availability of ventilator palliative support (1) . It has been proposed that the severity and mortality rates of the susceptible population infected by COVID-19 is related to a cytokine storm, in which an exaggerated production of pro-inflammatory substances are released into the pulmonary microenvironment over a short period of time (5) .
Novel life-saving strategies are desperately needed to mitigate the high mortality that is associated with the late stage viral infection with acute respiratory distress.
We hypothesize that the morbidity, severity of the disease, and underlying physiological events linked to mortality can be explained by the involvement of the TRPV1 expressing neuronal system (afferent/efferent neurons). TRPV1 positive pathways are responsible for pain transmission, inflammation and immunomodulation throughout the entire pulmonary system. We suggest that therapeutic approaches targeting TRPV1 expressing neurons in the lungs will modulate the inflammatory and immune signal activity, leading to reduced mortality and better overall outcomes. We propose to further explore the use of resiniferatoxin (RTX), an ultra-potent TRPV1 agonist currently in J o u r n a l P r e -p r o o f clinical trials for cancer and osteoarthritis pain, as a possible ablating agent of TRPV1 positive pulmonary pathways in patients with advanced COVID-19 disease.
Pathophysiology of COVID-19.
The clinical signs of COVID-19 are consistent with those observed in viral pneumonia.
Abnormal chest CT scans showing bilateral multiple peripheral ground-glass opacities has been observed in 98 % of hospital cases (2) . These pulmonary changes are likely responsible for both systemic and localized immune response leading to a hyperinflammatory state. The mortality rate in patients is suspected to be related to virally driven cytokine storm similar to that seen in SARS-CoV-2 infections. The cytokine storm is a result of a severe immune reaction in the lungs as measured by high levels of inflammatory markers (c-reactive protein, serum ferritin) and cytokine levels (IL-6, IL-2, IL-7, IL-10, GSCF, IP10, MCP1, MIP1A, and TNFα) in the plasma (1). ICU patients had higher plasma levels of IL-2, IL-7, IL-10, GSCF, IP10, MCP1, MIP1A, and TNFα as compared to non-ICU patients, suggesting that the presence of high circulating cytokine levels is associated with the severity of the disease (2, 5) . The current urgent need for effective treatment of this life-threatening disease by targeting hyper-inflammation in the lungs, is of high, compelling interest. Although use of corticosteroids might be beneficial in reducing inflammation-induced lung injury, evidence from SARS and MERS patients shows no or little improvement in mortality rates, with a delay in viral load clearance (6, 7) . An anti-inflammatory therapy using a monoclonal antibody against IL-6 is currently undergoing phase III trial in COVID-19 patients (8) and could lead to promising results.
The effectiveness of this therapy depends on the control of a single factor (IL-6) in this multidimensional process. It is possible that the approach will be limited in efficacy and J o u r n a l P r e -p r o o f it might be necessary to interfere with the inflammatory cascade at a higher level (i.e., eliminating the pro-inflammatory efferent pathway) to appropriately control the multimodal aspect of this inflammatory process.
Afferent innervation, TRPV1 channel and inflammation in the lungs.
The respiratory tract (higher and lower) is densely populated by sensory afferents originating from neurons in the nodose (vagal) ganglia (VG) and dorsal root ganglia (DRG). Many of the neurons in these ganglia express high levels of the transient receptor potential vanilloid 1 (TRPV1) ion channel. The crosstalk between TRPV1 positive nerve fibers and immune cells is critical in mediating inflammation of the airway following exposure to either inhaled allergens or viral infection (13, 14) . TRPV1 is strongly implicated in the regulation of irritant-induced airway responses and cough (15). The expression of TRPV1 positive cells is increased in the airways of patients with chronic cough (18). Activation of TRPV1 enhances the release of several proinflammatory molecules, including substance P (sP), and cytokines such as IL-6. Proinflammatory substances have reported to be upregulated in COVID-19 cases and reflect the severity of the disease (16) .
A recent study has demonstrated that respiratory viral infections (by rhinovirus, This finding suggests that ablation of TRPV1 positive pathways could be beneficial for the prevention or treatment of ventilator-associated lung injury. Hyperoxic acute lung injury (HALI) as a result of high inspired fraction of oxygen (FiO2) during prolong times, in addition to mechanical ventilation, will increase lung inflammation, microvascular permeability and lung epithelial apoptotic cell death (11) . An initiating factor involved in this type of lung injury is the generation of reactive oxygen species (ROS) that will activate a signaling cascade leading to overproduction of substance P (by TRPV1 activation) with subsequent increase in cytokines levels (12) . The role of TRPV1 positive cells in HALI has been described (12) 
Rationale for blocking afferent signaling (TRPV1) in COVID-19 patients:
We suggest that the association of TRPV1 expressing innervation combined with the virally driven hyperinflammation in COVID-19 cases might be the root cause of the lethal aspect of the disease particularly for the elderly. We propose that interrupting TRPV1 signaling might decrease the severity of the acute respiratory distress syndrome present in COVID-19 patients.
Studies in mice, with LPS-induced lung injury have shown that capsazepine (a TRPV1
antagonist) pre-treatment prevented the increase in respiratory system resistance, tissue damping, and decreased the area of collapsed lung parenchyma (19) . Blocking Silencing TRPV1 positive nerve fibers could eventually be also of interest to limit the progression of the disease from mild stages to acute respiratory distress.
Resiniferatoxin (RTX) potential to lessen impact of COVID-19 progression.
The afferent innervation of the pulmonary system is mainly conducted by the vagal nerve and its branches. TRPV1 expressing C-fibers are small diameter unmyelinated fibers in the vagal nerve and responsible for several processes in the airways and lungs. It is important to note that afferent fibers innervating pulmonary structure are also carried by sympathetic fibers with cell bodies located in the dorsal root ganglia of the thoracic segment between T1 and T6. The activation of this thoracic segment has been related to severe pneumonitis (21).
In consideration of pulmonary neuroanatomy, potential routes of administration for an ablative agent would include thoracic epidural injections, peri-ganglionic nerve block or intra-ganglionic injections for -chemical‖ targeted lung denervation (22) . A practical approach for example, would be to access the vagal nerve with a local ablative agent might be through the neck, going low, away from the carotid bulb. The nerve location would then be confirmed using ultrasound guidance. Pharmacology safety studies indicate that the resiniferatoxin mechanism of action is limited to those nerves involved with neurogenic inflammation (26) We propose to pursue an epidural or peri-ganglionic application of RTX in patients with advanced COVID-19 disease in support of current palliative ventilation therapy, in the hope that ablating afferent nerves at the thoracic DRG level will increase survival of patients progressing towards critical condition. As we have product available, an active IND and have treated more about 30 patients through central routes without significant adverse events, we believe there is enough safety data to justify pursuing an IND for this indication. We also will propose to explore other alternative peripheral approaches (nerve blocks) in collaboration with experts and with the appropriate regulatory authority oversight. 
